A technology company uses artificial intelligence to assist in cancer drug development has launched a study that will collect data on up to 1,000 blood cancer patients over the course of a year. San Francisco-based Notable said Wednesday it had launched the study, titled ANSWer, which will collect de-identified specimens with matched clinical data from participants in U.S. and Canadian clinical networks, at the time of their entry into the study and during subsequent visits. Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, multiple myeloma, lymphomas, myeloproliferative disorders and others will be included. The goal is to establish a tumor registry with annotated clinical outcomes. "The observational clinical trial that we're kicking off will give us the opportunity to test more patients than ever before, allowing us to continue increasing the platform's predictive value," Notable CEO Matt De Silva said in a statement.
Jan-23-2020, 19:19:53 GMT